Therapy Areas: Infectious Diseases
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
15 January 2024 -

Life science technology company PacBio (NASDAQ: PACB), a developer of precise sequencing solutions, on Monday announced the launch of its Nanobind PanDNA kit, expanding long-read sequencing capabilities to various sample types. This versatile kit covers cells, bacteria, blood, tissue, plant nuclei and insects, catering to diverse research needs.

The Nanobind kits, available in manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) configurations, enable efficient extraction of high-quality, high molecular weight DNA. The rapid protocol is compatible with automation platforms from PacBio's partners.

Responding to user feedback, the Nanobind HT CBB kit now supports two new sample types - animal blood and bacteria - accommodating 96 samples per run. The new PanDNA kit is set for availability and shipment in February 2024, while the Nanobind HT CBB kit is currently accessible.

PacBio specialises in advanced sequencing solutions for resolving genetically complex challenges across various research applications, including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology and emerging areas.